Ketorolac or triamcinolone injections for tendon and joint problems in the arm and hand
Compares ketorolac and triamcinolone injections for tendon or joint disease in the upper limb.
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, United StatesSee the 4 sites
- Trial code
- Registry title
- Ketorolac in Upper Extremity Tendinopathy and Arthropathy
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 160 people, planned
- Started
- 31 Jan 2023
- Expected to end
- Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Triamcinolone injection to the shoulder, elbow, wrist, or hand
- Ketorolac injection to the shoulder, elbow, wrist, or hand
- Record updated
- 3 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with painful tendon or joint problems of the shoulder, elbow, hand, or wrist. They get either a ketorolac or a triamcinolone injection.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Tendon disease (tendinopathy) or joint disease (arthropathy) of the shoulder, elbow, hand, or wrist that causes symptoms. Examples: trigger finger, De Quervain's tenosynovitis, wrist (radiocarpal) osteoarthritis, first carpometacarpal (CMC) joint osteoarthritis, metacarpophalangeal joint osteoarthritis, proximal interphalangeal joint osteoarthritis.
- Earlier treatment
- No past surgery for this condition. No triamcinolone or ketorolac injections in the past 6 months.
Main reasons for not taking part
- Under 18 years old
- Past surgery for the hand condition
- Triamcinolone or ketorolac injection in the past 6 months
- Allergy to triamcinolone or ketorolac, or another reason these injections cannot be given
- Active infection where the injection would go, such as skin infection, pus, fever, chills, or raised infection markers in blood tests (WBC, ESR, CRP)
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age 18 or older,
- symptomatic tendinopathy or arthropathy of the shoulder, elbow, hand, or wrist who have not undergone prior surgical treatment for their condition
- Diagnoses may include trigger finger, De Quervain's tenosynovitis, radiocarpal osteoarthritis, first carpometacarpal (CMC) joint osteoarthritis, metacarpophalangeal joint osteoarthritis, or proximal interphalangeal joint osteoarthritis
Who cannot take part
- Patients who have undergone prior triamcinolone or ketorolac injections within the past 6 months,
- Patients who have undergone prior surgical treatment for their hand condition,
- Patients with allergy or contraindication to triamcinolone or ketorolac injection,
- Patients with an active infection at the treatment site [active infection defined as cellulitis, purulence, fever, chills, or presence of elevated inflammatory markers, ie. white blood cells (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]
- Patients under the age of 18,
Where in United States
- 12 Executive Park DriveAtlanta, United StatesContact: Paul A. Ghareeb, MDTaking people
- Emory Saint Joseph's HospitalAtlanta, United StatesContact: Paul A. Ghareeb, MDTaking people
- Emory University Orthopaedic and Spine CenterAtlanta, United StatesContact: Amanda L Demsey, MDTaking people
- Emory University Orthopaedic and Spine HospitalAtlanta, United StatesContact: Paul A. Ghareeb, MDTaking people
About the trial
What the trial wants to find out
Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control and improved function in large joint OA. However, fewer studies yielding mixed results on the duration of symptomatic relief exist for arthropathy and tendinopathy of these joints.
Read full original descriptionShow less
The goal of this study is to evaluate the efficacy of ketorolac and triamcinolone injections for common shoulder, elbow, wrist, and hand tendinopathy or arthropathy.
Participants will be blinded to the treatment received. The duration of an individual participant's participation in this study is 24 weeks. During this time period, patients will be asked to return to the clinic for an in-person follow-up 6 weeks after the injection with either ketorolac or triamcinolone) in order to assess participants' outcomes. All work related to this project will take place at the Emory Sports Medicine Complex, Emory Executive Park, Emory Musculoskeletal Institute, the Emory University Orthopaedic and Spine Hospital, and the Emory Saint Joseph's Hospital. This study will add to existing knowledge by providing further insight into how wrist arthropathy should be most optimally and conservatively managed.
The 2 groups in the trial
- Triamcinolone injection to the shoulder, elbow, wrist, or handExisting treatment, for comparison
Participants will receive the triamcinolone injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
- Ketorolac injection to the shoulder, elbow, wrist, or handExisting treatment, for comparison
Participants will receive the Ketoralac injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy
- Plain-language title
- Ketorolac or triamcinolone injections for tendon and joint problems in the arm and handGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 3 September 2026